Gilead Sciences
Q2 2022 Earnings Call
Aug 02, 2022, 4:30 p.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good day, and thank you for standing by. Welcome to Gilead Sciences second quarter 2022 earnings conference call. [Operator instructions] Please be advised that today's call is being recorded. I would now like to hand the conference over to Jacquie Ross, vice president of investor relations.
Please go ahead.
Jacquie Ross -- Vice President, Investor Relations
Thank you, operator, and good afternoon, everyone. Just after market close today, we issued a press release with earnings results for the second quarter of 2022. The press release, slides, and supplemental data are available on the Investors section of our website at gilead.com. The speakers on today's call will be our chairman and chief executive officer, Daniel O'Day; our chief commercial officer, Johanna Mercier; our chief medical officer, Merdad Parsey; and our chief financial officer, Andrew Dickinson.
After that, we'll open up the call to Q&A where the team will be joined by Christi Shaw, the chief executive officer of Kite. Before we get started, let me remind you that we will be making forward-looking statements, including those related to the impact of the COVID-19 pandemic on Gilead's business; financial condition and results of operations; plans and expectations with respect to products, product candidates, corporate strategy, business and operations; financial projections and use of capital; and 2022 financial guidance, all of which involve certain assumptions, risks, and uncertainties that are beyond our control and could cause actual results to differ materially from these statements. A description of these risks can be found in the earnings press release and our latest SEC disclosure documents. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
Non-GAAP financial measures will be used to help you understand the company's underlying business performance. The GAAP to non-GAAP reconciliations are provided in the earnings press release, in our supplementary data sheet as well as on the Gilead website. Now I'll turn the call over to Dan.
Dan O'Day
Thanks, Jacquie, and good afternoon, everybody. We really appreciate you joining today. We look forward to sharing our second quarter results, which highlighted a quarter of strong commercial and clinical execution. This was a very strong quarter for our business, delivering revenue of US$6.1 billion.